NO318029B1 - Oralt, farmasoytisk preparat av piperidinoalkanol-forbindelser i opplosningsform, samt fremgangsmate for fremstilling derav - Google Patents
Oralt, farmasoytisk preparat av piperidinoalkanol-forbindelser i opplosningsform, samt fremgangsmate for fremstilling derav Download PDFInfo
- Publication number
- NO318029B1 NO318029B1 NO19975680A NO975680A NO318029B1 NO 318029 B1 NO318029 B1 NO 318029B1 NO 19975680 A NO19975680 A NO 19975680A NO 975680 A NO975680 A NO 975680A NO 318029 B1 NO318029 B1 NO 318029B1
- Authority
- NO
- Norway
- Prior art keywords
- approx
- oral pharmaceutical
- solution form
- solvent system
- pharmaceutical preparation
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 13
- 238000000034 method Methods 0.000 title claims description 7
- 150000001875 compounds Chemical class 0.000 title description 32
- 239000008203 oral pharmaceutical composition Substances 0.000 title 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 51
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 37
- 239000002904 solvent Substances 0.000 claims description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 25
- 239000008183 oral pharmaceutical preparation Substances 0.000 claims description 24
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 20
- 229960000583 acetic acid Drugs 0.000 claims description 18
- 239000012362 glacial acetic acid Substances 0.000 claims description 17
- 230000003287 optical effect Effects 0.000 claims description 4
- 239000000243 solution Substances 0.000 description 30
- 239000000825 pharmaceutical preparation Substances 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 239000000739 antihistaminic agent Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000850 decongestant Substances 0.000 description 4
- 230000001387 anti-histamine Effects 0.000 description 3
- 239000000043 antiallergic agent Substances 0.000 description 3
- 229940124630 bronchodilator Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000003434 antitussive agent Substances 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 229940124581 decongestants Drugs 0.000 description 2
- 229960001985 dextromethorphan Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 229940066493 expectorants Drugs 0.000 description 2
- 229940060367 inert ingredients Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229940127230 sympathomimetic drug Drugs 0.000 description 2
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- BCXHDORHMMZBBZ-DORFAMGDSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;sulfuric acid Chemical compound OS(O)(=O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC BCXHDORHMMZBBZ-DORFAMGDSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 229960003871 codeine sulfate Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002146 guaifenesin Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/469,392 US5574045A (en) | 1995-06-06 | 1995-06-06 | Oral pharmaceutical composition of piperidinoalkanol compounds in solution form |
| PCT/US1996/005968 WO1996039139A1 (en) | 1995-06-06 | 1996-04-30 | Oral pharmaceutical composition of piperidinoalkanol compounds in solution form |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO975680D0 NO975680D0 (no) | 1997-12-05 |
| NO975680L NO975680L (no) | 1998-02-05 |
| NO318029B1 true NO318029B1 (no) | 2005-01-24 |
Family
ID=23863607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19975680A NO318029B1 (no) | 1995-06-06 | 1997-12-05 | Oralt, farmasoytisk preparat av piperidinoalkanol-forbindelser i opplosningsform, samt fremgangsmate for fremstilling derav |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US5574045A (es) |
| EP (1) | EP0831820B1 (es) |
| JP (1) | JP4091655B2 (es) |
| KR (1) | KR100509316B1 (es) |
| CN (1) | CN1139386C (es) |
| AR (1) | AR002191A1 (es) |
| AT (1) | ATE256465T1 (es) |
| AU (1) | AU707218B2 (es) |
| CA (1) | CA2218643C (es) |
| DE (1) | DE69631132T2 (es) |
| DK (1) | DK0831820T3 (es) |
| ES (1) | ES2211954T3 (es) |
| HU (1) | HU227710B1 (es) |
| IL (1) | IL118525A (es) |
| MX (1) | MX9709453A (es) |
| NO (1) | NO318029B1 (es) |
| NZ (1) | NZ307370A (es) |
| PT (1) | PT831820E (es) |
| SI (1) | SI0831820T1 (es) |
| TW (1) | TW460283B (es) |
| WO (1) | WO1996039139A1 (es) |
| ZA (1) | ZA964517B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1148849A (zh) * | 1994-05-18 | 1997-04-30 | 赫彻斯特马里恩鲁斯公司 | 抗组胺哌啶衍生物，其多晶形物和假同晶物的无水和水合物形式的制备方法 |
| US20030045722A1 (en) * | 1994-05-18 | 2003-03-06 | Henton Daniel R. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
| EP0812195B1 (en) * | 1995-02-28 | 2002-10-30 | Aventis Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol compounds |
| ES2107375B1 (es) * | 1995-08-01 | 1998-07-01 | Almirall Prodesfarma Sa | Formulaciones farmaceuticas liquidas de ebastina por via oral. |
| US6451815B1 (en) | 1997-08-14 | 2002-09-17 | Aventis Pharmaceuticals Inc. | Method of enhancing bioavailability of fexofenadine and its derivatives |
| KR100514264B1 (ko) * | 1997-08-26 | 2005-09-15 | 아벤티스 파마슈티칼스 인크. | 피페리디노알칸올-충혈완화제 조합용 제약 조성물 |
| GB9822170D0 (en) * | 1998-10-13 | 1998-12-02 | Danbioyst Uk Ltd | Novel formulations of fexofenadine |
| US6613906B1 (en) * | 2000-06-06 | 2003-09-02 | Geneva Pharmaceuticals, Inc. | Crystal modification |
| US20060205752A1 (en) * | 2005-03-14 | 2006-09-14 | Keith Whitehead | Stabilized hydrocodone pharmaceutical compositions with ethylenediaminetetraacetic acid |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3806526A (en) * | 1972-01-28 | 1974-04-23 | Richardson Merrell Inc | 1-aroylalkyl-4-diphenylmethyl piperidines |
| US3878217A (en) * | 1972-01-28 | 1975-04-15 | Richardson Merrell Inc | Alpha-aryl-4-substituted piperidinoalkanol derivatives |
| US3966949A (en) * | 1973-10-12 | 1976-06-29 | Richardson-Merrell Inc. | Pharmaceutical compositions and preparing same |
| US4254129A (en) * | 1979-04-10 | 1981-03-03 | Richardson-Merrell Inc. | Piperidine derivatives |
| US4285957A (en) * | 1979-04-10 | 1981-08-25 | Richardson-Merrell Inc. | 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof |
| US4254130A (en) * | 1979-04-10 | 1981-03-03 | Richardson-Merrell Inc. | Piperidine derivatives |
| US4285958A (en) * | 1979-04-10 | 1981-08-25 | Richardson-Merrell Inc. | 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof |
| EP0111114A3 (de) * | 1982-11-06 | 1985-10-09 | Telefonbau und Normalzeit GmbH | Schaltungsanordnung für eine Fernsprechvermittlungsanlage, insbesondere Fernsprechnebenstellenanlage mit zusätzlichem Datenverkehr |
| DK164642C (da) * | 1984-08-30 | 1992-12-14 | Merrell Dow Pharma | Farmaceutisk middel indeholdende terfenadin i form af en varmsmelte paafyldt paa kapsler |
| US4929605A (en) * | 1987-10-07 | 1990-05-29 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol derivatives |
| US4999226A (en) * | 1988-06-01 | 1991-03-12 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination |
| AR245888A1 (es) * | 1989-01-23 | 1994-03-30 | Merrell Pharma Inc | Procedimiento para la preparacion de una composicion farmaceutica liquida de derivados de piperidinoalcanol. |
| US4966061A (en) * | 1989-03-27 | 1990-10-30 | Riera John F | Tube cutting apparatus |
-
1995
- 1995-06-06 US US08/469,392 patent/US5574045A/en not_active Expired - Lifetime
-
1996
- 1996-04-30 MX MX9709453A patent/MX9709453A/es unknown
- 1996-04-30 HU HU9802096A patent/HU227710B1/hu unknown
- 1996-04-30 KR KR1019970708985A patent/KR100509316B1/ko active IP Right Grant
- 1996-04-30 AU AU56695/96A patent/AU707218B2/en not_active Expired
- 1996-04-30 CA CA002218643A patent/CA2218643C/en not_active Expired - Lifetime
- 1996-04-30 SI SI9630667T patent/SI0831820T1/xx unknown
- 1996-04-30 NZ NZ307370A patent/NZ307370A/xx not_active IP Right Cessation
- 1996-04-30 EP EP96913862A patent/EP0831820B1/en not_active Expired - Lifetime
- 1996-04-30 AT AT96913862T patent/ATE256465T1/de active
- 1996-04-30 DE DE69631132T patent/DE69631132T2/de not_active Expired - Lifetime
- 1996-04-30 ES ES96913862T patent/ES2211954T3/es not_active Expired - Lifetime
- 1996-04-30 DK DK96913862T patent/DK0831820T3/da active
- 1996-04-30 CN CNB961944951A patent/CN1139386C/zh not_active Expired - Lifetime
- 1996-04-30 PT PT96913862T patent/PT831820E/pt unknown
- 1996-04-30 JP JP50050197A patent/JP4091655B2/ja not_active Expired - Lifetime
- 1996-04-30 WO PCT/US1996/005968 patent/WO1996039139A1/en active IP Right Grant
- 1996-05-31 ZA ZA964517A patent/ZA964517B/xx unknown
- 1996-06-01 TW TW085106573A patent/TW460283B/zh not_active IP Right Cessation
- 1996-06-02 IL IL11852596A patent/IL118525A/en not_active IP Right Cessation
- 1996-06-03 AR ARP960102864A patent/AR002191A1/es active IP Right Grant
-
1997
- 1997-12-05 NO NO19975680A patent/NO318029B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR19990022504A (ko) | 1999-03-25 |
| CN1139386C (zh) | 2004-02-25 |
| HUP9802096A3 (en) | 1999-06-28 |
| HU227710B1 (en) | 2011-12-28 |
| ES2211954T3 (es) | 2004-07-16 |
| DE69631132D1 (de) | 2004-01-29 |
| TW460283B (en) | 2001-10-21 |
| ZA964517B (en) | 1996-12-09 |
| CA2218643A1 (en) | 1996-12-12 |
| ATE256465T1 (de) | 2004-01-15 |
| KR100509316B1 (ko) | 2005-11-25 |
| IL118525A0 (en) | 1996-10-16 |
| EP0831820A1 (en) | 1998-04-01 |
| MX9709453A (es) | 1998-02-28 |
| NO975680L (no) | 1998-02-05 |
| CN1187125A (zh) | 1998-07-08 |
| AU5669596A (en) | 1996-12-24 |
| WO1996039139A1 (en) | 1996-12-12 |
| AU707218B2 (en) | 1999-07-08 |
| DE69631132T2 (de) | 2004-08-19 |
| JP4091655B2 (ja) | 2008-05-28 |
| JPH11506115A (ja) | 1999-06-02 |
| HUP9802096A2 (hu) | 1999-01-28 |
| EP0831820B1 (en) | 2003-12-17 |
| IL118525A (en) | 2001-07-24 |
| SI0831820T1 (en) | 2004-04-30 |
| NO975680D0 (no) | 1997-12-05 |
| DK0831820T3 (da) | 2004-04-13 |
| AR002191A1 (es) | 1998-01-07 |
| US5574045A (en) | 1996-11-12 |
| PT831820E (pt) | 2004-05-31 |
| CA2218643C (en) | 2001-12-11 |
| NZ307370A (en) | 1999-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR940011246B1 (ko) | 로라타딘, 이부프로펜 및 슈도에페드린을 함유하는 약제학적 조성물 | |
| AU2006295440B2 (en) | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients | |
| RU2423106C9 (ru) | Применение твердой пероральной дозировочной композиции пролонгированного действия для приготовления лекарственных средств | |
| EP0348683B1 (en) | Pharmaceutical compositions containing ibuprofen in combination with a piperidinoalkanol antihistamine | |
| DE69836424T2 (de) | Laktose-freie, nicht-hygroskopische und wasserfreie pharmazeutische zusammensetzungen von descarboethoxyloratadin | |
| US20090297598A1 (en) | Therapeutic combination | |
| US20030130297A1 (en) | Oral administration of 6-hydroxy-oxymorphone for use as an analgesic | |
| CA2608024A1 (en) | Use of flibanserin in the treatment of chronic pain | |
| JP2009538918A (ja) | フェニレフリンを含有する徐放薬学的投薬形態 | |
| JP2001515475A (ja) | 尿失禁、動揺病及びめまいの治療薬の製造のためのデスカルボエトキシロラタジンの使用 | |
| NO318029B1 (no) | Oralt, farmasoytisk preparat av piperidinoalkanol-forbindelser i opplosningsform, samt fremgangsmate for fremstilling derav | |
| JP2003267890A (ja) | 不整脈および発作の治療または防止における５−ｈｔ４受容体拮抗剤の使用 | |
| MXPA97009453A (es) | Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion | |
| JP3792251B2 (ja) | 手術後の悪心および嘔吐の治療のためのグラニセトロンの使用 | |
| US6680067B2 (en) | Controlled-release pharmaceutical preparation containing nalbuphine and a process for preparing the same | |
| JP2005187328A (ja) | イブプロフェン含有解熱鎮痛組成物、及び感冒薬 | |
| AU8915891A (en) | Dextromethorphan antitussive compositions | |
| JP2009539990A (ja) | Ｃｘｃｒ２またはｃｘｃｒ１とｃｘｃｒ２との両方のいずれかの選択的アンタゴニストの薬学的処方物および組成物ならびに炎症性障害を治療するためにそれらを使用する方法 | |
| US20080311196A1 (en) | All Day Rhinitic Condition Treatment Regimen | |
| AU2013201986A1 (en) | Capsule Formulation Of Pirfenidone And Pharmaceutically Acceptable Excipients | |
| JP2021536443A (ja) | 高血圧治療をサーカディアンリズムと同期させる | |
| WO1998058647A1 (en) | Acetaminophen and cisapride analgesics | |
| Nicholson | Antihistamines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |